WallStreetZen

NASDAQ: AZN
Astrazeneca Plc Earnings & Revenue

AZN past earnings growth

How has AZN's earnings growth performed historically?
Company
136.89%
Industry
13.35%
Market
37.79%
AZN's earnings have grown slower (1.82% per year) than the US Drug Manufacturers - General industry average (4.06%)
Performance
AZN's earnings have grown slower (1.82% per year) than the US market average (19.73%)
Performance
AZN's earnings growth is accelerating - its growth over the last year (136.89%) is above its 5-year compound annual rate (1.82%)
Performance

AZN past revenue growth

How has AZN's revenue growth performed historically?
Company
9.16%
Industry
12.11%
Market
20.26%
AZN's revenue has grown slower (1.5% per year) than the US Drug Manufacturers - General industry average (5.94%)
Performance
AZN's revenue has grown slower (1.5% per year) than the US market average (18.37%)
Performance
AZN's revenue growth is accelerating - its growth over the last year (9.16%) is above its 5-year compound annual rate (1.5%)
Performance

AZN earnings and revenue history

Current Revenue
$26.6B
Current Earnings
$3.1B
Current Profit Margin
11.8%
AZN's has not demonstrated consistent long-term earnings growth over the past 10 years (-56.43%)
Performance

AZN Return on equity

Current Company
24.7%
Current Industry
35.6%
Current Market
49.8%
AZN's Return on Equity (24.7%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

AZN Return on assets

Current Company
5.1%
Current Industry
6.9%
Current Market
5.4%
AZN is generating lower Return on Assets (5.1%) than the US Drug Manufacturers - General industry average (7.12%)
Performance

AZN Return on capital employed

Current Company
11.25%
Current Industry
11.1%
AZN has gotten more efficient at generating Return on Capital (11.25%) compared to 3 years ago (7.95%)
Performance

Astrazeneca Earnings & Revenue FAQ

What were AZN's earnings last quarter?

Astrazeneca (NASDAQ: AZN) reported Q4 2020 earnings per share (EPS) of $0.39, up 225% year over year. Total Astrazeneca earnings for the quarter were $1.01 billion. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $0.12.

What was AZN's earnings growth in the past year?

As of Q2 2021, Astrazeneca's earnings has grown 136.89% year over year. This is 123.54 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 13.35%. Astrazeneca's earnings in the past year totalled $3.14 billion.

What was AZN's revenue last quarter?

Astrazeneca (NASDAQ: AZN) reported Q4 2020 revenue of $7.41 billion up 11.19% year over year. In the same quarter last year, Astrazeneca's revenue was $6.66 billion.

What was AZN's revenue growth in the past year?

As of Q2 2021, Astrazeneca's revenue has grown 9.16% year over year. This is 2.95 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 12.11%. Astrazeneca's revenue in the past year totalled $26.62 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.